The tachykinin NK1 receptor antagonist GR205171 prevents vagal stimulation-induced retching but not neuronal transmission from emetic vagal afferents to solitary nucleus neurons in dogs

被引:23
作者
Fukuda, H [1 ]
Koga, T
Furukawa, N
Nakamura, E
Shiroshita, Y
机构
[1] Kawasaki Med Sch, Dept Physiol, Kurashiki, Okayama 70101, Japan
[2] Nippon Glaxo, Tsukuba Res Labs, Div Res, Pharmacol Dept,Sect 1, Tsukuba, Ibaraki 30042, Japan
关键词
tachykinin NK1; receptor antagonist; GR205171; substance P; vomiting; retching; solitary nucleus; vagus nerve;
D O I
10.1016/S0006-8993(98)00630-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Tachykinin NK1 receptor antagonists injected into the medulla oblongata are known to abolish vomiting induced by vagal afferent stimulation. Emetic vagal afferents have been shown to synapse with neurons in the medial solitary nucleus (mNTS), which suggests that substance P is a transmitter in the synapse. To examine this possibility, the effects of GR205171, an NK1 receptor antagonist, on retching and mNTS neuronal responses to the stimulation of abdominal vagal afferents were investigated in decerebrate dogs. GR205171 (0.05-0.7 mg kg(-1), i.v.) abolished retching induced by either vagal or mNTS stimulation within 5 min. Firing of mNTS neurons in response to pulse-train and sustained vagal stimulation did not change even after the abolition of retching. Similarly, GR205171 did not have any effects on mNTS evoked potentials induced by pulse-train vagal stimulation. In about 20% of mNTS neurons, the peak firing frequency was facilitated to about 150% with repetitive pulse-train vagal stimulation. This facilitation remained even after the abolition of retching. Administration of GR205171 (1 mg ml(-1), 30 mu l) into the 4th ventricle abolished retching, with latencies in excess of 120 min. These results suggest that substance P does not participate in synaptic transmission between emetic vagal afferents and mNTS neurons in dogs. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:221 / 231
页数:11
相关论文
共 42 条
[31]   BEHAVIOR OF INHIBITORY AND EXCITATORY PROPRIOBULBAR RESPIRATORY NEURONS DURING FICTIVE VOMITING [J].
MILLER, AD ;
EZURE, K .
BRAIN RESEARCH, 1992, 578 (1-2) :168-176
[32]  
NAYLOR RJ, 1992, COLLOQ INSE, V223, P115
[33]   WIND-UP AND THE NMDA RECEPTOR - FROM ANIMAL STUDIES TO HUMANS [J].
REN, K .
PAIN, 1994, 59 (02) :157-158
[34]   Capsaicin in the 4th ventricle abolishes retching and transmission of emetic vagal afferents to solitary nucleus neurons [J].
Shiroshita, Y ;
Koga, T ;
Fukuda, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 339 (2-3) :183-192
[35]   RATE OF RISE OF THE CUMULATIVE DEPOLARIZATION EVOKED BY REPETITIVE STIMULATION OF SMALL-CALIBER AFFERENTS IS A PREDICTOR OF ACTION-POTENTIAL WINDUP IN RAT SPINAL NEURONS INVITRO [J].
SIVILOTTI, LG ;
THOMPSON, SWN ;
WOOLF, CJ .
JOURNAL OF NEUROPHYSIOLOGY, 1993, 69 (05) :1621-1631
[36]   CAPSAICIN APPLICATION TO CENTRAL OR PERIPHERAL VAGAL FIBERS ATTENUATES CCK SATIETY [J].
SOUTH, EH ;
RITTER, RC .
PEPTIDES, 1988, 9 (03) :601-612
[37]   Enantiospecific inhibition of emesis induced by nicotine in the house musk shrew (Suncus murinus) by the neurokinin(1) (NK1) receptor antagonist CP-99,994 [J].
Tattersall, FD ;
Rycroft, W ;
Marmont, N ;
Cascieri, M ;
Hill, RG ;
Hargreaves, RJ .
NEUROPHARMACOLOGY, 1995, 34 (12) :1697-1699
[38]   THE TACHYKININ NK(1) RECEPTOR ANTAGONIST CP-99,994 ATTENUATES CISPLATIN-INDUCED EMESIS IN THE FERRET [J].
TATTERSALL, FD ;
RYCROFT, W ;
HARGREAVES, RJ ;
HILL, RG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 250 (01) :R5-R6
[39]   Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets [J].
Tattersall, FD ;
Rycroft, W ;
Francis, B ;
Pearce, D ;
Merchant, K ;
MacLeod, AM ;
Ladduwahetty, T ;
Keown, L ;
Swain, C ;
Baker, R ;
Cascieri, M ;
Ber, E ;
Metzger, J ;
MacIntyre, DE ;
Hill, RG ;
Hargreaves, RJ .
NEUROPHARMACOLOGY, 1996, 35 (08) :1121-1129
[40]   ENANTIOSELECTIVE INHIBITION OF APOMORPHINE-INDUCED EMESIS IN THE FERRET BY THE NEUROKININ(1) RECEPTOR ANTAGONIST CP-99,994 [J].
TATTERSALL, FD ;
RYCROFT, W ;
HILL, RG ;
HARGREAVES, RJ .
NEUROPHARMACOLOGY, 1994, 33 (02) :259-260